| 09th week of 2011 patent applcation highlights part 50 |
| Patent application number | Title | Published |
|---|
| 20110052572 | REGULATORS OF MMP-9 AND USES THEROF - A method of regulating an activity of metalloproteinase 9 (MMP-9) is disclosed. The method comprises contacting the MMP-9 with an agent which specifically interacts with an OG domain of the MMP-9. Molecules capable of specifically interacting with the OG domain, methods of identifying same, pharmaceutical compositions comprising same and uses thereof are also disclosed. | 2011-03-03 |
| 20110052573 | 14-3-3 ETA Antibodies and Uses Thereof for the Diagnosis and Treatment of Arthritis - The invention provides anti-14-3-3 eta antibodies that specifically bind to the human 14-3-3 eta protein isoform in its natural configuration while exhibiting selectivity over human 14-3-3 alpha, beta, delta, epsilon, gamma, tau, and zeta protein isoforms. Methods, kits and pharmaceutical compositions comprising said specific anti-14-3-3 eta antibodies are further provided for the diagnosis and treatment of arthritis. | 2011-03-03 |
| 20110052574 | METHOD OF INHIBITION OF LEUKEMIC STEM CELLS - A method for inhibition of leukemic stem cells expressing IL-3Rα; (CD 123), comprises contacting the cells with an antigen binding molecule comprising a Fc region or a modified Fc region having enhanced Fc effector function, wherein the antigen binding molecule binds selectively to IL-3Rα (CD123). The invention includes the treatment of a hematologic cancer condition in a patient by administration to the patient of an effective amount of the antigen binding molecule. | 2011-03-03 |
| 20110052575 | ANTI-VEGF ANTIBODIES - Humanized and variant anti-VEGF antibodies and various uses therefor are disclosed. The anti-VEGF antibodies have strong binding affinities for VEGF; inhibit VEGF-induced proliferation of endothelial cells in vitro; and inhibit tumor growth in vivo. | 2011-03-03 |
| 20110052576 | VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND THE TREATMENT OF EARLY STAGE TUMORS - Disclosed herein are methods of treating benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating a subject at risk of developing benign, pre-cancerous, or non-metastatic tumors using an anti-VEGF-specific antagonist. Also disclosed are methods of treating or preventing recurrence of a tumor using an anti-VEGF-specific antagonist as well as use of VEGF-specific antagonists in neoadjuvant and adjuvant cancer therapy. | 2011-03-03 |
| 20110052577 | Antibodies - The use of an ScFv Ab (ScFv Ab) capable of recognising a disease associated molecule (DAM) in the manufacture of a medicament for the prevention and/or treatment of a disease condition associated with a DAM is described. The ScFv Ab has therapeutic, diagnostic and prognostic applications. | 2011-03-03 |
| 20110052578 | Compounds and Compositions as Protein Kinase Inhibitors - The present invention provides compounds of Formula I or II: | 2011-03-03 |
| 20110052579 | Ligands of the Natural Killer (NK) Cell Surface Marker CD27 and Therapeutic Uses Thereof, - The present invention relates to the modulation of Natural Killer (NK) cells in vitro or in vivo through the use of activating or inhibiting ligands of CD27, such as antibodies, for a regulation of the immune response against several different diseases, such as viral infections, cancer, bacterial infections, sepsis as well as immunological diseases. In a preferred embodiment, the inventors were able to improve the host resistance against Influenza virus and cancer through the application of anti-CD27 antibodies. In a different setting the inventors were able to prevent the onset of a lethal bacterial sepsis by preventing the activation of NK cells via CD27. The invention furthermore relates to screening assays for ligands of the surface marker CD27. | 2011-03-03 |
| 20110052580 | USE OF PICOPLATIN AND BEVACIZUMAB TO TREAT COLORECTAL CANCER - The invention provides a method of treatment of metastatic colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with bevacizumab (Avastin®) and optionally, with 5-FU and leucovorin in a variety of treatment regimens. The invention also provides a use of picoplatin in conjunction with bevacizumab and, optionally, 5-FU and leucovorin, for the treatment of metastatic colorectal cancer. | 2011-03-03 |
| 20110052581 | USE OF PICOPLATIN AND CETUXIMAB TO TREAT COLORECTAL CANCER - The invention provides a method of treatment of metastatic colorectal cancer by administration of the anti-cancer platinum drug picoplatin in conjunction with cetuximab, 5-FU, and leucovorin in a variety of treatment regimens. The invention also provides a use of picoplatin in conjunction with cetuximab, 5-FU, and leucovorin for treatment of metastatic colorectal cancer. The invention further provides kits adapted for administration of picoplatin in conjunction with cetuximab. Also, methods for determining dosage regimens for patients afflicted with a cancer comprising EGFR are provided. | 2011-03-03 |
| 20110052582 | Humanized Anti-CDCP1 Antibodies - The present invention relates to humanized antibodies against human CDCP1 (anti-CDCP1 antibody), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 2011-03-03 |
| 20110052583 | PYRIDINONE COMPOUNDS - The invention is directed to pyridinone compounds useful for modulating Met kinase, having the following structure: | 2011-03-03 |
| 20110052584 | METHOD OF ENHANCEMENT OF CYTOTOXICITY IN ANTIBODY MEDIATED IMMUNE RESPONSES - The present invention is related to enhancing the function of anti-tumor antibodies by regulating FcγRIIB-mediated activity. In particular, disrupting SHIP activation by FcγRIIB enhances cytotoxicity elicited by a therapeutic antibody in vivo in a human. The invention further provides an antibody, e.g., an anti-tumor antibody, with a variant Fc region that results in binding of the antibody to FcγRIIB with reduced affinity. A variety of transgenic mouse models demonstrate that the inhibiting FcγRIIB molecule is a potent regulator of cytotoxicity in vivo. | 2011-03-03 |
| 20110052585 | COMPOSITIONS AND METHODS FOR INHIBITING INTERLEUKIN PATHWAYS - Fusion proteins including an IL-17 receptor with a multimerization domain, or an IL-23 receptor and a multimerization domain, and recombinant viral vectors encoding such fusions, are described. The fusion proteins and vectors encoding such fusions, alone or in combination, can be used in methods for modulating the IL-17 and IL-23 signaling pathways and for treating or preventing diseases mediated by interleukin-17 and interleukin-23, such as immune-related and inflammatory diseases. | 2011-03-03 |
| 20110052586 | ANTIBODIES TO AN EPITOPE OF AGR2, ASSAYS AND HYBRIDOMAS - Provided is a monoclonal antibody, or an antigen binding fragment thereof, which binds specifically to an epitope within the sequence KPGAKKDTKDSRPKL (Sequence ID No. 2) of AGR2. Such monoclonal antibodies are of prognostic and diagnostic utility in the investigation of cancer, particularly metastatic cancer. The antibodies described may also be used in prognosis or diagnosis of inflammatory diseases. Also provided are kits and solid supports comprising such antibodies, as well as the therapeutic use of antibodies of the invention. | 2011-03-03 |
| 20110052587 | PEPTIDE OR PROTEIN COMPRISING A C'-D LOOP OF THE CD28 RECEPTOR FAMILY - The invention relates to a protein or peptide comprising the C′-D loop of a member of the CD28 family, uses thereof and mAbs obtainable therefrom. | 2011-03-03 |
| 20110052588 | METHOD OF TREATING HEPATOCELLULAR CARCINOMA - Materials and methods for treating hepatocellular carcinoma in a mammal are disclosed. The methods comprise administering to a mammal a composition comprising a therapeutically effective amount of a zvegf3 antagonist in combination with a pharmaceutically acceptable delivery vehicle. Zvegf3 antagonists include anti-zvegf3 antibodies, mitogenically inactive receptor-binding zvegf3 variant polypeptides, and inhibitory polynucleotides. | 2011-03-03 |
| 20110052589 | COMPOSITIONS AND METHODS FOR DETECTING AND TREATING DISEASES AND CONDITIONS RELATED TO CHEMOKINE RECEPTORS - Ligands of CCX-CKR2 and the biological role of CCX-CKR2 in cancer is described. | 2011-03-03 |
| 20110052590 | NEUTROKINE-ALPHA ANTIBODIES AND METHODS OF USE THEREOF - The present invention relates to a Neutrokine-alpha antibody and a process for producing a Neutrokine-alpha antibody. The invention further relates to screening methods for identifying compounds that inhibit or enhance the action of Neutrokine-alpha. Also provided are diagnostic methods for detecting autoimmune disorders and therapeutic methods for treating autoimmune disorders using a Neutrokine-alpha antibody. | 2011-03-03 |
| 20110052591 | Variants of Thyroid Stimulating Hormone Beta - Polynucleotide and polypeptide sequences that encode novel variants of mouse or human thyroid stimulating hormone-β proteins are disclosed that can be used in therapeutic, diagnostic, and pharmacogenomic applications to prevent, treat or reduce the severity of thyroid stimulating hormone-β-related disorders. | 2011-03-03 |
| 20110052592 | Compositions and Methods for Use for Antibodies Against Sclerostin - The present invention relates to antibodies against sclerostin and compositions and methods of use for said antibodies to treat a pathological disorder that is mediated by sclerostin or disease related to bone abnormalities such as osteoporosis. | 2011-03-03 |
| 20110052593 | BREAST CANCER ASSOCIATED ANTIGEN - The invention relates to nucleic acid and amino acid sequences encoding BUC11 (SEQ ID NO: 36), BUC6 (SEQ ID NO: 31), BUC9 (SEQ ID NO: 32), and BUC10 (SEQ ID NO: 35), and to the use of such sequences in the identification and treatment of cancers. | 2011-03-03 |
| 20110052594 | AGENTS THAT DISSOLVE ARTERIAL THROMBI - Agents that induce platelet fragmentation include an IgG antibody that reacts with platelet epitope GPIIIA49-66 on platelet membrane, recombinant AMANTS-18, phorbol 12-myristate 13-acetate (PMA) and A23817. | 2011-03-03 |
| 20110052595 | MONOCLONAL ANTIBODY CAPABLE OF BINDING TO HEPARIN-BINDING EPIDERMAL GROWTH FACTOR-LIKE GROWTH FACTOR - Medicaments for treating diseases related to HB-EGF escalation are in demand. The present invention provides a monoclonal antibody or an antibody fragment thereof which binds to a cell membrane-bound HB-EGF, a membrane type HB-EGF and a secretory HB-EGF. | 2011-03-03 |
| 20110052596 | ANTIBODIES TO IL-17A - Engineered antibodies to human IL-17A are provided, as well as uses thereof. | 2011-03-03 |
| 20110052597 | Anti-IL-13R Alpha1 Antibodies and Their Uses Thereof - Antibody antagonists of human interleukin-13 receptor alpha 1 which bind to hIL-13Rα1 through domain 3 of the extracellular region of the receptor and inhibit IL-13 receptor-mediated signaling by IL-13 are disclosed herein. These antibodies have uses inter alia in the treatment or prevention of IL-13-related disorders and diseases. The present invention also discloses nucleic acid encoding said antibody molecules, vectors, host cells, and compositions comprising the antibody molecules. Methods of using the antibody molecules for inhibiting or antagonizing hIL-13Rα1-mediated activities are also disclosed. | 2011-03-03 |
| 20110052598 | METHOD FOR SCREENING OF THERAPEUTIC AGENT FOR ALLERGIC AIRWAY INFLAMMATION AND/OR AIRWAY HYPERSENSITIVITY USING IL-17RB-POSITIVE NKT CELL - The invention provides a method of screening a therapeutic agent for allergic airway inflammation and/or airway hypersensitivity, comprising using an IL-17RB positive NKT cell, as well as a therapeutic agent for allergic airway inflammation and/or airway hypersensitivity, containing a substance capable of inhibiting or eliminating the Th2 cell-like function of an IL-17RB positive NKT cell as an active ingredient. | 2011-03-03 |
| 20110052599 | Facilitation of Oocyte, Zygote and Pre-Implantation Embryo Maturation - Compositions and methods are provided for enhancing the survival and promoting the maturation of mammalian oocytes, zygotes and preimplantation embryos. BDNF or BDNF agonists may be administered to an individual, or to cells in vitro, to enhance cellular maturation, embryo growth and fertilization. Accordingly, compositions comprising BDNF are herein presented for use in promoting in vivo oocyte maturation as well as for use as a component in culture media for promoting preimplantation maturation of zygotes and embryos, for instance, for use with in vitro fertilization procedures and for the production of stem cells. Additionally, compounds that interfere with the binding of BDNF to its receptor may be administered to an individual to prevent oocyte maturation, thereby acting as a contraceptive. The BNDF receptor, TrkB, and BDNF also find use in the screening and design of agonists and antagonists for use in the methods of the invention. | 2011-03-03 |
| 20110052600 | IL-17RA-IL-17RB ANTAGONISTS AND USES THEREOF - The present invention relates to Interleukin-17 ligand and receptor family members and the discovery that IL-17 receptor A and IL-17 receptor C form a heteromeric receptor complex that is biologically active. Antagonists of the IL-17RA-IL-17RB heteromeric receptor complex are disclosed, as well as various methods of use. | 2011-03-03 |
| 20110052601 | COMPOSITIONS COMPRISING ANTI-ICAM-1 ANTIBODIES - There is provided a method of preventing a respiratory infection by administering an effective amount of an agent for regulating ICAM-1 expression. Also provided is a composition for the prevention of respiratory infection including an agent which regulates ICAM expression. method of preventing RSV infection by administering an effective amount of an agent that interferes with the binding of RSV to ICAM-1. A method of preventing RSV infection by administering an effective amount of an agent that down regulates the expression of ICAM-1, thereby decreasing RSV binding to ICAM-1 is also provided. There is provided a method of treating RSV infection by administering an effective amount of an agent for down regulating ICAM-1 expression. A method of blocking RSV-ICAM-1 interaction by administering an effective amount of agents for blocking ICAM sites of binding is provided. Also provided is a compound for blocking RSV-ICAM-1 interaction including an agent for blocking ICAM sites of binding. | 2011-03-03 |
| 20110052602 | Diagnosis and Treatment of Age Related Macular Degeneration - Methods, compositions and kits for diagnosis and treatment of age related macular degeneration. | 2011-03-03 |
| 20110052603 | METHOD OF TREATMENT AND AGENTS USEFUL FOR SAME - The present invention relates generally to a method of modulating tumor necrosis factor-mediated apoptosis and to agents useful for same. More particularly, the present invention contemplates a method of modulating tumor necrosis factor-mediated hepatocyte apoptosis by modulating an intracellular Bim and/or Bid-dependent signalling mechanism. The method of the present invention is useful, inter alia, in the treatment and/or prophylaxis of conditions characterized by aberrant, unwanted or otherwise inappropriate tumor necrosis factor-mediated apoptosis. The present invention is further directed to methods for identifying and/or designing agents capable of modulating the subject Bim and/or Bid-dependent signalling mechanism. | 2011-03-03 |
| 20110052604 | Human Anti-OPGL Neutralizing Antibodies as Selective OPGL Pathway Inhibitors - Monoclonal antibodies and hybridomas producing them that interact with osteoprotegerin ligand (OPGL) are provided. Methods of treating osteopenic disorders by administering a pharmaceutically effective amount of antibodies to OPGL are also provided. Methods of detecting the amount of OPGL in a sample using antibodies to OPGL are further provided. | 2011-03-03 |
| 20110052605 | ASSAY FOR SOLUBLE CD200 - The disclosure relates to methods for identifying a subject having elevated CD200 levels and/or comprising cells overexpressing CD200, the method comprising the step of assaying a biological fluid from the subject to determine a level of soluble CD200, wherein a level above control indicates the subject has elevated CD200 levels. Diagnostic methods, methods of monitoring prognosis and methods of medical treatment relating to CD200 associated medical conditions are also provided. The disclosure also provides assays and kits useful in the diagnosis of a medical condition associated with elevated CD200 and/or comprising cells overexpressing CD200. | 2011-03-03 |
| 20110052606 | Humanized Anti-Human NKG2A Monoclonal Antibody - The present invention relates to agents that are non-competitive antagonists of the CD94/NKG2A receptor such as certain anti-NKG2A antibodies, in particular humanized versions of murine anti-NKG2A antibody Z199, as well as methods of producing and using such agents and antibodies. | 2011-03-03 |
| 20110052607 | METHODS OF DIAGNOSING MYELODYSPLASTIC SYNDROME (MDS) OR LEUKEMIA USING NUCLEIC ACIDS OR FRAGMENTS ENCODING FLT3 KINASE - To provide a nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane and is useful for diagnosis of leukemia; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to a region encoded by the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a nucleic acid capable of specifically binding to the nucleic acid having tandem duplication occurring in a nucleotide sequence of a juxtamembrane; a method for detection of the nucleic acid encoding a receptor protein kinase; and a kit therefor. A nucleic acid encoding a receptor protein kinase, wherein the nucleic acid has tandem duplication in a nucleotide sequence of a juxtamembrane; a polypeptide encoded by the nucleic acid; an antibody capable of specifically binding to the portion of the polypeptide; a nucleic acid capable of specifically binding to the nucleic acid; a method for detection of the nucleic acid; and a kit for detection. | 2011-03-03 |
| 20110052608 | NOVEL ANTIBODIES AGAINST PRION PROTEIN AND USES THEREOF - The present invention relates to a novel antibody which selectively binds to the disease associated form of prion protein (PrP | 2011-03-03 |
| 20110052609 | MAGNETIC TRANSDUCERS - Embodiments herein relate to the production of biocompatible magnetic nanoparticles with a high SAR-value which produce a large amount of heat when exposed to an alternating magnetic field. The produced heat can be used among others for therapeutic purposes, in particular for combating cancer. | 2011-03-03 |
| 20110052610 | ANTIBODY COMPOSITION EXHIBITING CELLULAR CYTOTOXICTY DUE TO GLYCOSYLATION - The present invention relates to a cell for the production of an antibody molecule such as an antibody useful for various diseases having high antibody-dependent cell-mediated cytotoxic activity, a fragment of the antibody and a fusion protein having the Fc region of the antibody or the like, a method for producing an antibody composition using the cell, the antibody composition and use thereof. | 2011-03-03 |
| 20110052611 | PEPTIDE CONJUGATE COMPOSITIONS AND METHODS FOR THE PREVENTION AND TREATMENT OF ALZHEIMER'S DISEASE - The invention provides compositions and methods for the treatment of diseases associated with amyloid deposits of Aβ in the brain of a patient, such as Alzheimer's disease. Such methods entail administering an immunogenic fragment of Aβ, lacking a T-cell epitope, capable of inducing a beneficial immune response in the form of antibodies to Aβ. In another aspect, the immunogenic fragment of Aβ is capable of elevating plasma Aβ levels. The immunogenic fragments comprise linear or multivalent peptides of Aβ. Pharmaceutical compositions comprise the immunogenic fragment chemically linked to a carrier molecule which may be administered with an adjuvant. | 2011-03-03 |
| 20110052612 | SPIROPIPERIDINE COMPOUND AND MEDICINAL USE THEREOF - The present invention relates to a CXCR3 antagonist comprising a compound represented by formula (I) (wherein all the symbols have the same meaning as defined in the description), | 2011-03-03 |
| 20110052613 | METHOD FOR THE TREATMENT OF NEUROLOGICAL DISORDERS BY ENHANCING THE ACTIVITY OF BETA-GLUCOCEREBROSIDASE - Provided is a method of increasing the stability of wild-type β-glucocerebrosidase. Also provided are methods of treating and/or preventing an individual having a neurological disease in which increased expression or activity of β-glucocerebrosidase in the central nervous system would be beneficial. This method comprises administering an effective amount of a pharmacologic chaperone for β-glucocerebrosidase, with the proviso that the individual does not have a mutation in the gene encoding β-glucocerebrosidase. Further provided are β-glucocerebrosidase inhibitors which have been identified as specific pharmacologic chaperones and which have been shown to increase activity of β-glucocerebrosidase in vivo in the central nervous system. | 2011-03-03 |
| 20110052614 | STAT3 EPITOPE PEPTIDES - The present invention provides peptides comprising the amino acid sequence of SEQ ID NO: 3, 4, 5, 6, 7, 8, 9, 10, 11, 13, 14, 16, 17, 19, 20, 21, 22, 26, 27, 29, 30, 59, 61, 63, 64, 65, 66, 67, 68, 69, 70, 72, 73, 74, 75, 77, 83, 94, 96, 97, 98 or 103, and peptides comprising one of the above-mentioned amino acid sequences with substitution or addition of one, two, or several amino acids, and having cytotoxic T cell inducibility, and also provides drugs comprising these peptides. The peptides of this invention can be used as vaccines. | 2011-03-03 |
| 20110052615 | TUMOUR-SPECIFIC ANIMAL PROTEINS - CASB7439 polypeptides and polynucleotides, immunogenic compositions comprising them and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing CASB7439 polypeptides and polynucleotides in diagnostics, and vaccines for prophylactic and therapeutic treatment of cancers, particularly colorectal cancers, autoimmune diseases, and related conditions. | 2011-03-03 |
| 20110052616 | Biological materials and uses thereof - The present invention concerns a peptide molecule or a nucleic acid molecule, for use in medicine and, in particular, for use in preventing or treating a non-cancerous condition or relieving pain in a patient. The invention also relates to a pharmaceutical composition comprising the peptide or nucleic acid molecule of the invention and methods of treatment thereof. | 2011-03-03 |
| 20110052617 | AAV SCLEROPROTEIN, PRODUCTION AND USE THEREOF - The invention relates to a structural protein of adeno-associated virus (AAV) which comprises at least one mutation which brings about an increase in the infectivity of the virus. | 2011-03-03 |
| 20110052618 | INFLUENZA HEMAGGLUTININ AND NEURAMINIDASE VARIANTS - Polypeptides, polynucleotides, methods, compositions, and vaccines comprising (avian pandemic) influenza hemagglutinin and neuraminidase variants are provided. | 2011-03-03 |
| 20110052619 | METHODS OF VACCINE ADMINISTRATION, NEW FELINE CALICIVIRUSES, AND TREATMENTS FOR IMMUNIZING ANIMALS AGAINST FELINE PARAOVIRUS AND FELINE HERPES VIRUS - The present invention relates to a vaccine for immunizing a cat against feline viruses. The present invention also relates to a nucleic acid clone that encodes the capsid protein of the isolated feline calicivirus. The present invention further relates to a live or killed vaccine comprising the isolated feline calicivirus, a subunit vaccine comprising the capsid protein of the isolated feline calicivirus, a nucleic acid vaccine comprising a nucleic acid clone of the isolated feline calicivirus, and a recombinant virus vector vaccine comprising nucleic acid encoding the capsid protein of the isolated feline calicivirus. The present invention also relates to a method for identifying a feline calicivirus useful for producing a vaccine composition and for assays for diagnosing cats infected with feline calicivirus. Also disclosed is a method of immunizing animals, especially cats, against disease, in particular against feline calicivirus (FCV). The method includes administering to a cat therapeutically effective amounts of first and second FCV vaccines. The first vaccine is administered orally or parenterally (e.g., subcutaneously, intramuscularly, and the like). The second vaccine is administered orally or oronasally N days following administration of the first vaccine, wherein N is an integer from 3 to 120, inclusive. A third vaccine administration may also be given. The present invention also describes methods and materials for treating and immunizing animals with vaccine, and in particular cats against both FPV or Feline Parvovirus, which has also been called Panleukopenia or FPL and against another disease, FHV or Feline Herpes Virus, which has also been called Feline Rhinotracheitis Virus. | 2011-03-03 |
| 20110052620 | HYBRID POLYPEPTIDES COMPRISING GBS-80 AND SPB1 PROTEINS OF STREPTOCOCCUS - GBS antigens GBS-80 and Spb1 are expressed in a single polypeptide chain, preferably with Spb1 upstream of GBS-80. Thus the invention provides a polypeptide comprising an amino acid sequence NH | 2011-03-03 |
| 20110052621 | PCSK9 VACCINE - The present invention relates to the provision of novel immunogens comprising an antigenic PCSK9 peptide linked to an immunogenic carrier for the prevention, treatment or alleviation of PCSK9-mediated disorders. The invention further relates to methods for production of these medicaments, immunogenic compositions and pharmaceutical compositing thereof and their use in medicine. | 2011-03-03 |
| 20110052622 | REISHI-MEDIATED ENHANCEMENT OF HUMAN TISSUE PROGENITOR CELL ADHESION AND DIFFERENTIATION - The present disclosure provides medicinally active extracts and fractions, and methods for using the same to increase eukaryotic cell adhesion, to increase differentiation of eukaryotic cells to produce increased numbers of immature dendritic cells, to enhance or accelerate condrogenesis of MSCs, to maintain undifferentiated CD | 2011-03-03 |
| 20110052623 | DRIED MICROBIAL CELLS OR MICROORGANISM EXTRACT CONTAINING STABILIZED (SS)-S-ADENOSYL-L-METHIONINE AND METHOD FOR PRODUCTION OF THE DRIED MICROORGANISM CELL OR MICROORGANISM EXTRACT - Dried microbial cells or microbial extract containing (SS)-SAM in which the progress in SAM chemical degradation or (SS)-SAM epimerization is significantly delayed can be obtained by drying microbial cells or microbial extract containing S-adenosyl-L-methionine (SAM), followed by maturing treatment. It is possible to stabilize SAM in a composition comprising dried microbial cells or microbial extract containing SAM (1% by weight or more) without the need of strict environment control. | 2011-03-03 |
| 20110052624 | Type 5 And Type 8 Capsular Polysaccharides Of Overproducing S. Aureus Strains - The invention relates to the type 5 and type 8 capsular polysaccharides produced by overproducing | 2011-03-03 |
| 20110052625 | COMPOSITIONS AND METHODS FOR TREATING DIABETES USING LISOFYLLINE ANALOGS AND ISLET NEOGENESIS ASSOCIATED PEPTIDE - Pharmaceutical compositions and methods are provided for treating diabetes and/or restoring β-cell mass and function in a mammal in need thereof. Type 1 diabetes mellitus (T1DM) is an autoimmune disorder characterized by immune damage to pancreatic beta-cells. Lisofylline analogs (LSF analogs) are immunomodulators that reduce interlukin 12 signaling and reduce the onset of T1DM in non-obese diabetic (NOD) mice. A combination therapy with both LSF analog (pretreatment) and INGAP provides protection from autoimmune destruction. The concomitant or combination of an LSF analog and INGAP after pre-treatment with an LSF analog is an effective therapy for a disease or condition resulting from the loss of pancreatic islet cells or insulin production in a mammal. | 2011-03-03 |
| 20110052626 | LEPORIPOXVIRUS-DERIVED VACCINE VECTORS - The invention relates to modified leporipoxyinises expressing a chimeric envelope protein resulting from the fusion of an envelope protein of mature intracellular virions or of an envelope protein of enveloped extracellular virions, with an exogenous protein. These modified leporipoxviruses can be used in particular for obtaining vaccines. | 2011-03-03 |
| 20110052627 | RECOMBINANT MODIFIED VACCINIA VIRUS MEASLES VACCINE - The invention concerns methods, compositions and kits for use in preparing a medicament and vaccine for measles virus comprising an Attenuated Modified Vaccinia Virus Ankara (MVA) strain encoding hemagglutinin protein, fusion protein, and nucleoprotein of measles virus (MVA-Measles). The recombinant virus induced superior cellular and humoral responses to the measles virus when compared to Measles vaccine Rouvax®. Both T cell and B cell immune responses to the recombinant MVA were observed not only in adult animals, but also in newborn and juvenile animals. Results in adult humans showed that MVA-Measles induces a strong immune response, is safe and well tolerated. | 2011-03-03 |
| 20110052628 | Recombinant Double-Stranded RNA Phage, and Use of the Same - A recombinant double stranded RNA (dsRNA) phage expresses dsRNA-encoded genes in eukaryote cells. Recombinant dsRNA phage are useful for the expression of dsRNA expression cassettes encoding passenger genes, such as, but not restricted to, vaccine antigens, bioactive proteins, immunoregulatory proteins, antisense RNAs, and catalytic RNAs in eukaryotic cells or tissues. Methods are provided to deliver recombinant dsRNA phage to eukaryotic cells and tissues, either by direct administration, formulated in lipid or polylactide-coglycolide, or by utilizing a bacterial vaccine vector. | 2011-03-03 |
| 20110052629 | METHODS OF REDUCING CONCOMITANT INFECTIONS IN PIGS WITH A PCV2 ANTIGEN - The present invention relates to a method for reducing the percentage of concomitant infections in pigs or a herd of pigs caused by pathogens other than PCV2 comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. It also refers to a method for improving the resistance of pigs against concomitant infections with pathogens other than PCV2, comprising the step administering to said pig(s) an effective amount of PCV2 antigen or an immunogenic composition comprising PCV2 antigen. | 2011-03-03 |
| 20110052630 | Compositions and Methods Using Herpes Simplex Virus - Provided herein are methods and compositions for use in treating HSV-related conditions and diseases. | 2011-03-03 |
| 20110052631 | INDUCTION OF PROLIFERATION, EFFECTOR MOLECULE EXPRESSION, AND CYTOLYTIC CAPACITY OF HIV-SPECIFIC CD8+ T CELLS - Provided is a method of activating an immune cell of a subject with Human Immunodeficiency Virus (HIV), comprising contacting the immune cell with a phorbol ester and a calcium ionophore. Also provided is a composition comprising immune cells of a subject diagnosed with HIV, wherein the immune cells are activated by contact with a phorbol ester and a calcium ionophore. Methods of using the disclosed compositions are also disclosed. | 2011-03-03 |
| 20110052632 | HIV POLYNUCLEOTIDES AND POLYPEPTIDES DERIVED FROM BOTSWANA MJ4 - The present disclosure relates to novel polynucleotides that encode HIV Env polypeptides. In particular, the disclosure relates to sequences derived from HIV strain Botswana MJ4 encoding Env polypeptides. Compositions comprising these polynucleotides and methods of using these polynucleotides are also disclosed. | 2011-03-03 |
| 20110052633 | MULTI-PHASE EMULSIONS BASED ON AMPHIPHILIC BLOCK COPOLYMERS - An composition comprises (a) a continuous aqueous phase; (b) an oily phase; and (c) an amphiphilic emulsifying system comprising a block copolymer having the formula (A)p-(B)q-(C)r, in which (B)q is a hydrophilic block and (C)r is a hydrophobic block; wherein p, q and r are integers with the proviso that: if p is 0, then A is other than hydroxyl or reactive functional groups and the block copolymer is a diblock copolymer; B and C are each individual repeating) units; if p is >1, then the block copolymer is a triblock copolymer, in which (A)p is a hydrophobic block; the hydrophobic blocks (A)p and (C)r are each homopolymers or heteropolymers; the repeating units A and C are the same or different; and wherein the ratio q/(p+r) is sufficient high so that the hydrophilic-lipophilic balance value of the block copolymer is >10. | 2011-03-03 |
| 20110052634 | Attenuated recombinant alphaviruses incapable of replicating in mosquitoes and uses thereof - The present invention discloses an attenuated recombinant alphavirus that is incapable of replicating in mosquito cells and of transmission by mosquito vectors. These attenuated alphavirus may include but is not limited to Western Equine Encephalitis virus, Eastern equine encephalitis virus, Venezuelan equine encephalitis virus or Chikungunya virus. The present invention also discloses the method of generating such alphaviruses and their use as immunogenic compositions. | 2011-03-03 |
| 20110052635 | LIVE ATTENUATED SALMONELLA VACCINE - The present invention is related to double and triple attenuated mutant strains of a bacterium infecting veterinary species such as | 2011-03-03 |
| 20110052636 | METHOD FOR TREATING PREMATURE EJACULATION WITH A BOTULINUM NEUROTOXIN - Methods for prolongation of climax time in a patient in need thereof are presented, as are methods for treating premature ejaculation by local administration of a Clostridial neurotoxin, such a | 2011-03-03 |
| 20110052637 | PROTEINS EXPRESSED BY MYCOBACTERIUM TUBERCULOSIS AND NOT BY BCG AND THEIR USE AS VACCINES - The present invention is directed to proteins expressed by | 2011-03-03 |
| 20110052638 | ALLERGENS FROM ASPERGILLUS VERSICOLOR, AND METHOD OF DETECTING A MOLD ALLERGY CAUSED BY INTERIOR ROOMS - The invention relates to seven allergens of | 2011-03-03 |
| 20110052639 | ALLERGEN MUTANTS - Novel recombinant allergens with multiple mutations and reduced IgE binding affinity are disclosed. The allergens are mutants of naturally occurring allergens. The overall α-carbon backbone tertiary structure is essentially preserved. Also disclosed is a method for preparing such recombinant allergens as well as uses thereof. | 2011-03-03 |
| 20110052640 | HYPOALLERGENIC HYBRID PROTEINS OF MAJOR GROUP 1 AND 2 MITE ALLERGENS FOR USE IN THE TREATMENT OF ALLERGIES - The present invention refers to recombinant ADN molecules coding to hybrids polypeptides of different allergens from | 2011-03-03 |
| 20110052641 | HALOGENATED ALIPHATIC CARBOXYLIC ACIDS, OLIGOMERS AND/OR POLYMERS THEREOF AND THEIR USE IN DEVITALIZING EXTERNAL AND INTERNAL NEOPLASMS - Halogenated aliphatic carboxylic acids, salts and/or oligomers or polymers thereof, which exhibit a devitalizing effect of neoplastic tissues, are disclosed. Methods and uses that utilize these compounds for the treatment of medical conditions associated with a neoplastic tissue are also disclosed. Further disclosed are methods and uses that utilize these compounds for reducing or abolishing blood and lymph as well local dissemination of malignant neoplastic cells during a surgical removal thereof, thereby preventing recurrences and distance metastases, and/or inducing immune response to potentially malignant, pre-malignant and/or malignant cells. Further disclosed are novel oligomeric forms of halogenated aliphatic carboxylic acids, pharmaceutical compositions containing same and uses thereof. | 2011-03-03 |
| 20110052642 | PERIPHERAL ZONE TUMOR CELLS, METHODS FOR THEIR PREPARATION AND USE - The present invention relates to a tumor cell of the peripheral zone of a tumor and methods of providing such a tumor cell. Further provided is a method for identifying a molecular marker diagnostic for an infiltrative cancer, an antibody, which specifically binds to such molecular marker, a method for identifying a therapeutic compound effective against a metastatic/infiltrative cancer disease and the use of a tumor cell according to the invention. | 2011-03-03 |
| 20110052643 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES - The invention relates to certain fused ring compounds, or pharmaceutically acceptable salts thereof, that are useful as immunosuppressive agents and for treating and preventing inflammatory conditions, allergic disorders, and immune disorders. | 2011-03-03 |
| 20110052644 | COMPOSITION COMPRISING EXTRACT OF CINNAMOMUM CASSIA BARK FOR IMPROVING NORMAL FLORA AND ENHANCING IMMUNE RESPONSE - The present invention relates to a composition for improving intestinal flora and enhancing immune response containing | 2011-03-03 |
| 20110052645 | MANUFACTURE OF MULTIPLE MINICAPSULES - An extrusion process comprises extruding a material that is flowable when heated and passing the extrudate thus formed through a nozzle | 2011-03-03 |
| 20110052646 | POLYMER ADHESIVE FILM FOR DIRECTED CELLULAR GROWTH - The described embodiments relate to a polymer adhesive film having a micro-pattern arranged on a first surface of the polymer adhesive film for application to wounded tissue to promote directional cell growth. The micro-pattern is sized to allow cells of the wounded tissue to grow directionally within the micro-pattern to promote rapid and complete healing. | 2011-03-03 |
| 20110052647 | Antidepressant Oral Pharmaceutical Compositions - Novel enteric compositions suitable for oral administration comprising Duloxetine or its pharmaceutical derivatives thereof and methods for preparing such compositions are disclosed. Such compositions contain a core consisting of a Duloxetine or its pharmaceutical derivatives thereof, the said core comprised of a pharmaceutically inert nuclei and the Duloxetine or its pharmaceutical derivatives thereof compressed together, an intermediate and an enteric layer. Duloxetine or its pharmaceutical derivatives thereof may be any pharmaceutically acceptable prodrug, salt, solvate or derivative of Duloxetine. The novel compositions prepared according to the present invention have enhanced stability and bioavailability. | 2011-03-03 |
| 20110052648 | ORAL MODIFIED-RELEASE FORMULATIONS CONTAINING THIAZEPINES - An oral modified-release formulation using Quetiapine or pharmaceutically acceptable salts thereof as an active ingredient, while avoiding the use of a gelling material. As used herein, the term “modified release” includes but is not limited to one or more of controlled release, sustained release, prolonged release and extended release. | 2011-03-03 |
| 20110052649 | FINE POWDER OF POLYAMIDE FROM RENEWABLE MATERIALS AND METHOD FOR MAKING SUCH A POWDER - The present invention relates to a powder of polyamide PA (homopolyamide or copolyamide) derived at least partially from renewable materials, in which the particles have a nonspherical shape and a volume median diameter of less than or equal to 20 μm. The present invention also relates to a process for preparing such a powder. | 2011-03-03 |
| 20110052650 | POROUS CRYSTALLINE HYBRID SOLID FOR ADSORBING AND RELEASING GAS OF BIOLOGICAL INTEREST - The invention relates to solids made of a porous crystalline metal-organic framework (MOF) loaded with at least one gas of biological interest, and to a method for preparing the same. The MOF solids of the present invention are capable of adsorbing and releasing in a controlled manner gases having a biological interest. They can be used in the pharmaceutical field and/or for applications in the cosmetic field. They can also be used in the food industry. | 2011-03-03 |
| 20110052651 | ANTIMICROBIAL COMPOSITIONS AND PRODUCTS - The present disclosure provides antimicrobial compositions for use in textiles, as well as methods of preparing these compositions and treating textiles with these compositions. | 2011-03-03 |
| 20110052652 | Solid pharmaceutical composition comprising agglomerated nanoparticles and a process for producing the same - The present invention relates to pharmaceutical compositions comprising at least one active ingredient delivered by a nanoparticle. More specifically, the invention relates to solid pharmaceutical compositions comprising nanoparticles, wherein the nanoparticles are in the form of agglomerates with elevated equivalent aerodynamic diameters. The invention further relates to a process for producing such nanoparticles. | 2011-03-03 |
| 20110052653 | MULTI-PURPOSE ITEM REST - A multipurpose item rest having a bottom sheet with a non-absorbent surface with an absorbent pad fixedly attached thereto, an outwardly extending tab integral to the bottom sheet having an adhesive area such that the rest may be formed into a restraining device by applying the adhesive are to the bottom surface of the bottom sheet, and a supply of such item rests comprising one or more continuous strips of rests joined with perforated attachments. | 2011-03-03 |
| 20110052654 | MICROENCAPSULATED INSECTICIDE FORMULATIONS - Various microencapsulated insecticide formulations for the control of pests such as aphids and beet army worm. These formulations exhibit excellent knockdown activity towards both chewing and non-chewing pests as LD | 2011-03-03 |
| 20110052655 | METHODS AND VESICLES FOR CONTROLLING PROTOZOA - A method for controlling protozoa trophozoites and cysts wherein one or more biocides or non-biocidal agents are encapsulated within a micro-capsule or nano-capsule and then introduced into an aqueous system. The micro-capsule or nano-capsule has an exterior composition adapted for digestion by the protozoa. A vesicle for controlling protozoa trophozoites and cysts is also provided. | 2011-03-03 |
| 20110052656 | METHOD FOR CONTROLLING MICROBIAL BIOFILM IN AQUEOUS SYSTEMS - A process has been found which increases the efficiency and effectiveness of introducing antimicrobial compounds into complex biofilm matrices through the use of liposome carriers, thereby removing the biofouling in industrial water bearing systems, including piping, heat exchanges, condensers, filtration systems and fluid storage tanks. According to one embodiment of the invention, antimicrobial compound containing liposomes are added to water systems prone to biofouling and biofilm formation. The liposomes, being similar in composition to microbial membranes or cells, are readily incorporated into the existing biofilm. Once the antimicrobial compound containing liposomes become entrained with the biofilm matrix, the decomposition or programmed disintegration of the liposome proceeds. Thereafter, the biocidal aqueous core is released to react directly with the biofilm encased microorganisms. Upon the death of the organisms, the polysaccharide/protein matrix decomposes and thereby results in reduced fouling of the water bearing system, resulting in increased heat transfer, increased flux, less deposit of colloidal and particulate solids and dissolved organics on the surface of the microfiltration membrane, thereby reducing the frequency and duration of the membrane cleaning and ultimate replacement. | 2011-03-03 |
| 20110052657 | Implants for administering substances and methods of producing implants - A porous silicon implant impregnated with a beneficial substance, such as a micromineral required for healthy physiology, is implanted subcutaneously and is entirely corroded away over the following months/year to release the micromineral in a controlled manner. In a second embodiment the implant may have a large number of holes which contain beneficial substance and which are closed by bio-errordable doors of different thickness so as to stagger the release of the beneficial substance over time as the doors are breached. | 2011-03-03 |
| 20110052658 | MK2 INHIBITOR COMPOSITIONS AND METHODS TO ENHANCE NEURITE OUTGROWTH, NEUROPROTECTION, AND NERVE REGENERATION - The described invention provides compositions comprising at least one peptide of formula I for enhancing neurite outgrowth, neuroprotection, and nerve regeneration, and methods of use thereof. | 2011-03-03 |
| 20110052659 | Implants for administering substances and methods of producing implants - A porous silicon implant impregnated with a beneficial substance, such as a micromineral required for healthy physiology, is implanted subcutaneously and is entirely corroded away over the following months/year to release the micromineral in a controlled manner. In a second embodiment the implant may have a large number of holes which contain beneficial substance and which are closed by bio-errordable doors of different thickness so as to stagger the release of the beneficial substance over time as the doors are breached. | 2011-03-03 |
| 20110052660 | CERAMIC SCAFFOLDS FOR BONE REPAIR - Ceramic articles as functional biodegradable scaffolds with graded porosity are made by a process that includes a hardening step in which the liquid of a liquid-containing ceramic composition is extracted from the ceramic composition by exposing the ceramic composition to a solvent in which the liquid in the composition is soluble before the ceramic composition is solidified into the final ceramic article. An exemplary calcium phosphate porous ceramic article constructed in accordance with the process is useful as an implant to repair a bone defect. | 2011-03-03 |
| 20110052661 | PET DENTAL HYGIENE PRODUCT - An edible product for oral hygiene of a pet, the product being chewable by the pet to remove plaque, tartar and stain from the teeth of the pet and to reduce breath odor of the pet. The dental hygiene product includes a body formed of a first set of constituent components and a second set of constituent components, the first set of constituent components including abrasive components and one or more breath freshening components, the combination when chewed by the pet effecting the removal of plaque, tartar and stain and the inhibition of breath odor, the second set of constituent components including an abrasive component and one or more active components, the abrasive component when chewed by the pet effecting the removal of plaque, tartar and stain from the teeth of the pet, the one or more active components being characterized by the active components disrupting growth of bacteria in the pet's mouth thereby inhibiting plaque and tartar formation and breath odor from a bacterial source. | 2011-03-03 |
| 20110052662 | ANTIBACTERIAL MATERIAL AND ANTIBACTERIAL FILM AND ANTIBACTERIAL MEMBER USING THE SAME - In one embodiment, an antibacterial material includes at least one microparticles selected from tungsten oxide microparticles and tungsten oxide complex microparticles. The microparticles, which are undergone a test to evaluate viable cell count by inoculating in a test piece, to which the microparticles are adhered in a range of 0.02 mg/cm | 2011-03-03 |
| 20110052663 | Hemostatic Sponge with Enzyme and Method of Manufacture - In one embodiment, a method of making a wound dressing comprises dissolving at least one hemostatic agent in at least one solvent to form a solution. The method continues by freeze drying the solution to form a sponge. The method further comprises including an enzyme in the sponge that enables a human body to readily degrade the hemostatic agent. | 2011-03-03 |
| 20110052664 | Antimicrobial Medical Dressings and Protecting Wounds and Catheter Sites - An antimicrobial medical dressing provides a combination of antimicrobial agents in various concentrations that protect against microorganisms, absorb exudates, and promote healing. The antimicrobial agents may include compositions of ethanol, hydrogen peroxide, and/or ethylenediaminetetraacetic acid. | 2011-03-03 |
| 20110052665 | HAEMOSTATIC MATERIAL - The present invention relates to a haemostatic material comprising a carrier layer and a material for wound contact comprising at least one haemostat in particulate, granular, powder, flake or short fibrous form. Such a haemostatic material is useful, for example, in reducing or stopping bleeding of a physiological target site in a person or animal, and can also be used to stem bleeding during medical procedures. | 2011-03-03 |
| 20110052666 | Compositions, Methods, and Systems for SIRNA Delivery - The instant invention provides silencer expression cassettes for delivery of RNAi therapy. The silencer cassettes of the instant invention encode an RNAi agent and lack means for replication within a host cell, inverted terminal repeats and further lacking one or more selectable markers. Optionally, the silencer cassettes lack CpG dinucleotides and/or the RNAi agent is within a scaffold of a naturally occurring miRNA. The composition comprising the silencer cassettes of the instant invention, as well as methods of use and suitable systems are also provided. | 2011-03-03 |
| 20110052667 | COMPOSITIONS AND METHODS FOR INHIBITING ANGIOGENESIS AND TUMORIGENESIS - The present invention relates to the regulation of angiogenesis and tumorigenesis. The invention further relates to methods for identifying and using agents, such as small organic molecules, antibodies, peptides and nucleic acids (e.g., antisense molecules, RNAi molecules and ribozymes), that modulate angiogenesis and tumorigenesis via modulation of IGF-II and, in turn, EphB4, as well as to the use of expression profiles and compositions in the diagnosis and therapy of angiogenesis and cancer. | 2011-03-03 |
| 20110052668 | Identification and Characterization of a Specific CCK-C Receptor Antibody for Human Pancreatic Cancer and Its Use for Early Detection and Staging of Pancreatic Cancer - Human pancreatic cancer cells possess a distinct plasma membrane CCK receptor variant that can be differentiated from the classic CCK-B receptor with selective monoclonal antibodies. Use of this receptor may be helpful in early detection or treatment of patients with pancreatic cancer. | 2011-03-03 |
| 20110052669 | METHODS FOR MODULATING DE NOVO HEPATIC LIPOGENESIS BY MODULATING XBP-1 ACTIVITY - The invention provides methods and compositions for modulating the expression, processing, post-translational modification, stability and/or activity of XBP-1 protein, or a protein in a signal transduction pathway involving XBP-I to treat dyslipidemias and steatosis disorders. The present invention also pertains to methods for identifying compounds that modulate the expression, processing, post-translational modification, and/or activity of XBP-I protein or a molecule in a signal transduction pathway involving XBP-1. | 2011-03-03 |
| 20110052670 | IDENTIFICATION OF A PLURIPOTENT PRE-MESENCHYMAL, PRE-HEMATOPOIETIC PROGENITOR CELL - The present invention provides a molecular marker for the identification of pluripotent pre-mesenchymal, pre-hematopoietic stem cells. The invention further provides primitive progenitor cells identified by the molecular marker. Such cells have the potential to differentiate into both mesenchymal and hematopoietic phenotypes, as determined by a proliferative response to inductive growth factors and cytokines, and by their morphologic and cytochemical features. | 2011-03-03 |
| 20110052671 | NEAR INFRA-RED PULSED LASER TRIGGERED DRUG RELEASE FROM HOLLOW NANOSHELL DISRUPTED VESICLES AND VESOSOMES - The disclosure provides drug delivery methods and compositions. More particularly, the application provides liposomal delivery compositions comprising a nanostructure. | 2011-03-03 |
